person
Stefan H.
- Country
- Italy
- Department
- UOSD Malattie linfoproliferative extramidollari
Research Overview
assignment
21
Clinical Trials ·
- A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination with R-CHP in Participants with DLBCL (waveLINE)
- Phase 3 Randomized Study of Tirabrutinib Versus Rituximab-Temozolomide in Relapsed/Refractory Primary Central Nervous System Lymphoma
- Phase 1b/2 Study of MK-1045 Monotherapy and MK-1045 Plus Tocilizumab in Adults with Relapsed/Refractory Non‑Hodgkin Lymphoma
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
164
Sites with multiple studies
Has run more than one trial at 164 of 328 partner sites.
Specializations
B-Cell Lymphoma Research
The investigator specializes in treating diffuse large B-cell lymphoma (DLBCL), with particular focus on developing innovative therapeutic approaches for both newly diagnosed and relapsed/refractory cases.
- Advanced treatment combinations
- Novel therapeutic agents
- Immunochemotherapy protocols
Follicular Lymphoma Studies
Conducts research in follicular lymphoma treatment, exploring various therapeutic strategies including early-stage interventions and advanced disease management.
- Combination therapies
- Radiotherapy approaches
- High tumor burden treatments
Specialized Lymphoma Treatment
Focuses on treating distinct lymphoma subtypes including Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas.
- Advanced classical Hodgkin lymphoma
- T follicular helper cell phenotypes
- EBV-positive lymphomas
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.